|
MechanismBacterial DNA gyrase inhibitors [+2] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.DE |
First Approval Date28 May 2020 |
|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date14 Nov 1983 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date28 Sep 1972 |
A Randomized, Open-label Phase I Clinical Study to Evaluate the Systemic Pharmacokinetics and Safety of Atropine Sulfate Eye Drops in Healthy Chinese Volunteers
To evaluate the systemic pharmacokinetics and the safety of atropine sulfate eye drops in healthy volunteers.
评价硫酸阿托品滴眼液在中国健康志愿者中全身药代动力学和安全性的随机、开放标签I期临床研究
[Translation] A randomized, open-label phase I clinical study to evaluate the systemic pharmacokinetics and safety of atropine sulfate eye drops in Chinese healthy volunteers.
本研究的主要目的是评估健康志愿者单剂量给药硫酸阿托品滴眼液的全身药代动力学。次要目的是评估健康志愿者单剂量和多剂量给药硫酸阿托品滴眼液的安全性。
[Translation] The primary objective of this study was to evaluate the systemic pharmacokinetics of atropine sulfate eye drops administered as a single dose in healthy volunteers. A secondary objective was to evaluate the safety of single-dose and multiple-dose administration of atropine sulfate eye drops in healthy volunteers.
A Phase 3, Multicenter, Randomized, Double-masked, Active Controlled Study to Evaluate the Efficacy and Safety of Epinastine Hydrochloride Eye Drops 0.05% in the Treatment of Chinese Seasonal Allergic Conjunctivitis Patients
The goal of this multicenter, randomized, double-blind, active control, non-inferiority clinical trial is to evaluate the efficacy of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis using azelastine hydrochloride eye drops as a positive control in Chinese patients. The main question it aims to answer are:
• Is the efficacy for of epinastine hydrochloride eye drops for the treatment of seasonal allergic conjunctivitis non-inferior to azelastine hydrochloride eye drops?Participants will be randomly assigned to the test group or control group in a 1:1 ratio. The test group was treated with epinastine hydrochloride eye drops + azelastine hydrochloride simulating eye drops, and the control group was treated with azelastine hydrochloride eye drops + epinastine hydrochloride simulating eye drops, which were used twice a day for 14 consecutive days.
100 Clinical Results associated with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.
0 Patents (Medical) associated with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.
100 Deals associated with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.
100 Translational Medicine associated with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd.